Clinical trials: Peripheral Nervous System Agents
Haematologic Neoplasms
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in…
- Trial name
- NCT07064122
- Testing
- AZD2962
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Breast Cancer, Solid Tumors, Adult
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid…
- Trial name
- PIKALO-1 (NCT05768139)
- Testing
- STX-478, Fulvestrant, Ribociclib
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 880 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease, Coronary Artery Disease
Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease
Although both enteric-coated and plain formulations of aspirin are being used commonly, there are no high-quality comparisons between these formulations with respect to clinical efficacy outcomes in patients with atherosclerotic…
- Conditions
- Atherosclerotic Cardiovascular Disease, Coronary Artery Disease, Ischemic Heart Disease, Ischemic Stroke
- Trial name
- COATED-AIR (NCT06541691)
- Testing
- Enteric-coated aspirin, Plain aspirin, Hybrid strategy
- Where
- Iran
- Volunteers
- 3,000 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Nicotine Withdrawal, Marijuana Dependence
Medications Development for the Treatment of Cannabis Related Disorders
The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
- Conditions
- Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence, Nicotine Dependence
- Trial name
- MTC (NCT01204723)
- Testing
- Active Aprepitant
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Atrial Fibrillation, Permanent Atrial Fibrillation
Rate Control in Atrial Fibrillation II
The RATAF II study is a randomized, prospective, parallel group study, designed to compare the effects of two different drug regimens for rate control in permanent AF (atrial fibrillation).
- Trial name
- RATAFII (NCT02695992)
- Testing
- Metoprolol, Diltiazem
- Where
- Norway
- Volunteers
- 122 people
- Sponsor
- Asker & Baerum Hospital
Acute Pain
A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery
This is a single-center, randomized, double blind, placebo controlled, parallel group proof of concept study to evaluate the analgesic efficacy as well as the safety, tolerability and pharmacokinetic profile of CR845 in patients…
- Trial name
- NCT01789476
- Testing
- CR845
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Cara Therapeutics, Inc.
Underdosing of Local Anesthetics, Anesthetics, Local
Determination of Minimum Effective Volume of Local Anesthetic in Patients Undergoing Ultrasound-Guided Infraclavicular Approach for Brachial Plexus Blockade
Peripheral nerve blocks with use of USG allowed visualisation of the structures and nerves and made the block administrations safe, quick and comfortable.
- Conditions
- Underdosing of Local Anesthetics, Anesthetics, Local, Peripheral Nervous System Agents, Physiological Effects of Drugs
- Trial name
- NCT03838120
- Testing
- Procedure/Surgery: bupivakain % 0,5
- Volunteers
- 48 people
- Sponsor
- Ankara City Hospital Bilkent
Behavioral Symptoms, Suicide
Natural History of Depression, Bipolar Disorder and Suicide Risk
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments.
- Conditions
- Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents
- Trial name
- NCT06462196
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Mental Health (NIMH)
Carpal Tunnel Syndrome
Lidocaine With Epinephrine vs. Bupivacaine With Epinephrine as Local Anesthetic Agents in Wide-awake Hand Surgery
This study is focused on comparing patients' pain scores on a visual analogue scale (VAS) and the difference in analgesics use post-operatively (with the same prescription defining only the maximum frequency) between lidocaine…
- Trial name
- NCT02315573
- Testing
- Wrist block anesthesia
- Where
- Canada
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- St. Mary's Research Center, Canada
Severe Depression, Moderate Depression
Nebulized Ketamine for the Treatment of Major Depressive Disorder
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
- Conditions
- Severe Depression, Moderate Depression, Ketamine, Midazolam
- Trial name
- NCT06752759
- Testing
- nebulized ketamine, nebulized midazolam
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Theresa Jacob, PhD, MPH
Treatment Resistant Depression, Major Depressive Disorder
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine
- Trial name
- NCT05615948
- Testing
- VTS-K
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Theresa Jacob, PhD, MPH
Eosinophilic Esophagitis
Expanded Access Protocol for Patients With Eosinophilic Esophagitis
This expanded access program is an open-label, single-arm design where consenting patients may participate up until APT-1011 is commercially available in the relevant regions or the protocol is terminated by the Sponsor.
- Trial name
- NCT05095116
- Testing
- APT-1011 3 mg HS
- Where
- 35 sites in United States
- Sponsor
- Ellodi Pharmaceuticals, LP
Pre-diabetes
Resveratrol and First-degree Relatives of Type 2 Diabetic Patients
The main objective of the study is to investigate if resveratrol supplementation can improve overall and muscle-specific insulin sensitivity in first-degree relatives of type 2 diabetic patients.
- Trial name
- NCT02129595
- Testing
- resveratrol
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Maastricht University Medical Center
Pain, Postoperative, Analgesics, Opioid
Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy
A blinded randomized control trial in living kidney donors. The study group will receive a liposomal bupivacaine Trans Quadratus Lumborum (TQL) block after the induction of general anesthesia.
- Conditions
- Pain, Postoperative, Analgesics, Opioid, Analgesics, Non-Narcotic, Physiological Effects of Drugs
- Trial name
- NCT03294109
- Testing
- Abdominal wall block with liposomal bupivicaine
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Multiple Myeloma, Neoplasm, Plasma Cell
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT).
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms
- Trial name
- NCT04309084
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Celularity Incorporated
Breast Cancer, Colorectal Cancer
Chemotherapy-Induced Peripheral Neuropathy Survey
The goal of this research study is to learn more about pain and other symptoms that patients may experience while receiving chemotherapy treatment with platinum agents, taxanes, and/or bortezomib.
- Conditions
- Breast Cancer, Colorectal Cancer, Myeloma, Chemotherapy-induced Peripheral Neuropathy
- Trial name
- NCT01016028
- Testing
- Questionnaire, Sensory Tests, Interview
- Sponsor
- M.D. Anderson Cancer Center
Postoperative Pain
Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery
The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.
- Trial name
- NCT01361568
- Testing
- CR845
- Where
- 18 sites in United States
- Volunteers
- 203 people
- Sponsor
- Cara Therapeutics, Inc.
HR+ HER2- Breast Cancer
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants…
- Trial name
- NCT07558733
- Testing
- Serabelisib, Sapanisertib, Fulvestrant
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Faeth Therapeutics
Sciatica
Safety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica
The purpose of this study is to determine whether anti-inflammatory drugs or glucocorticoids are effective in the treatment of acute sciatica
- Trial name
- TéAGS (NCT01816334)
- Testing
- methylprednisolone, Ketoprofen, Sodium Chloride
- Where
- 2 sites in France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Advanced Solid Tumors, Advanced Breast Cancer
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
- Trial name
- NCT06993844
- Testing
- ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
- Where
- 15 sites in United States, China
- Volunteers
- 233 people
- Sponsor
- Ensem Therapeutics